» Articles » PMID: 16945909

The Iminosugar Isofagomine Increases the Activity of N370S Mutant Acid Beta-glucosidase in Gaucher Fibroblasts by Several Mechanisms

Overview
Specialty Science
Date 2006 Sep 2
PMID 16945909
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

Gaucher disease is a lysosomal storage disorder caused by deficiency in lysosomal acid beta-glucosidase (GlcCerase), the enzyme responsible for the catabolism of glucosylceramide. One of the most prevalent disease-causing mutations, N370S, results in an enzyme with lower catalytic activity and impaired exit from the endoplasmic reticulum. Here, we report that the iminosugar isofagomine (IFG), an active-site inhibitor, increases GlcCerase activity 3.0 +/- 0.6-fold in N370S fibroblasts by several mechanisms. A major effect of IFG is to facilitate the folding and transport of newly synthesized GlcCerase in the endoplasmic reticulum, thereby increasing the lysosomal pool of the enzyme. In addition, N370S GlcCerase synthesized in the presence of IFG exhibits a shift in pH optimum from 6.4 to 5.2 and altered sensitivity to SDS. Although IFG fully inhibits GlcCerase in the lysosome in an in situ assay, washout of the drug leads to partial recovery of GlcCerase activity within 4 h and full recovery by 24 h. These findings provide support for the possible use of active-site inhibitors in the treatment of some forms of Gaucher disease.

Citing Articles

High-throughput screening for small-molecule stabilizers of misfolded glucocerebrosidase in Gaucher disease and Parkinson's disease.

Williams D, Glasstetter L, Jong T, Chen T, Kapoor A, Zhu S Proc Natl Acad Sci U S A. 2024; 121(42):e2406009121.

PMID: 39388267 PMC: 11494340. DOI: 10.1073/pnas.2406009121.


Development of quantitative high-throughput screening assays to identify, validate, and optimize small-molecule stabilizers of misfolded β-glucocerebrosidase with therapeutic potential for Gaucher disease and Parkinson's disease.

Williams D, Glasstetter L, Jong T, Kapoor A, Zhu S, Zhu Y bioRxiv. 2024; .

PMID: 38712038 PMC: 11071283. DOI: 10.1101/2024.03.22.586364.


A practical synthesis of nitrone-derived C5a-functionalized isofagomines as protein stabilizers to treat Gaucher disease.

Li H, Chen W, Lin H, Tsai C, Chiu Y, Yun W Commun Chem. 2024; 7(1):91.

PMID: 38643239 PMC: 11032326. DOI: 10.1038/s42004-024-01164-9.


GBA1 Variants and Parkinson's Disease: Paving the Way for Targeted Therapy.

Huh Y, Usnich T, Scherzer C, Klein C, Chung S J Mov Disord. 2023; 16(3):261-278.

PMID: 37302978 PMC: 10548077. DOI: 10.14802/jmd.23023.


Precision Medicine in Parkinson's Disease: From Genetic Risk Signals to Personalized Therapy.

Straccia G, Colucci F, Eleopra R, Cilia R Brain Sci. 2022; 12(10).

PMID: 36291241 PMC: 9599944. DOI: 10.3390/brainsci12101308.


References
1.
Jonsson L, Murray G, Sorrell S, Strijland A, Aerts J, Ginns E . Biosynthesis and maturation of glucocerebrosidase in Gaucher fibroblasts. Eur J Biochem. 1987; 164(1):171-9. DOI: 10.1111/j.1432-1033.1987.tb11008.x. View

2.
Brady R, Kanfer J, Bradley R, Shapiro D . Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J Clin Invest. 1966; 45(7):1112-5. PMC: 292783. DOI: 10.1172/JCI105417. View

3.
Grabowski G, White W, Grace M . Expression of functional human acid beta-glucosidase in COS-1 and Spodoptera frugiperda cells. Enzyme. 1989; 41(3):131-42. DOI: 10.1159/000469068. View

4.
Aerts J, Hollak C, Boot R, Groener J, Maas M . Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis. 2006; 29(2-3):449-56. DOI: 10.1007/s10545-006-0272-5. View

5.
Sawkar A, DHaeze W, Kelly J . Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease. Cell Mol Life Sci. 2006; 63(10):1179-92. PMC: 11136070. DOI: 10.1007/s00018-005-5437-0. View